CAR-T & Beyond: Future Cell Based Immunotherapeutic Strategies
15:30am Chair Introduction
Chairperson: Sven Kili, Principal, Sven Kili Consulting
15:35am Presentation: Natural Killer Cell Based Therapies: Lessons Learned
- Cover autologous and allogeneic clinical trials performed
- Discuss strategies around NK cell persistence and efficacy
- Role of donor and patient selection algorithms
Evren Alici, Head of Cell and Gene Therapy Group, Department of Medicine, Karolinska Institutet
15:50am Presentation: From Vision to Reality: Stemmatters’ Role in Supporting Development and Manufacturing of an Innovative Cone Replacement Therapy for Central Vision Loss
Rui A. Sousa, Chief Executive Officer & Chairman, Stemmatters
16:05am Presentation: A Personal Vaccine Platform Technology for Cancer and Infectious Disease
- Dendritic cell vaccines are being manufactured as therapeutic anti-cancer vaccines and as anti-viral vaccines using antigens from self-renewing autologous cancer cells, and immunogenic proteins.
- Promising data from cancer trials includes safety, induction of immune responses, tumor regressions, and increased progression free and overall survival
- Promising data from COVID-19 trials demonstrated fewer and lower-grade adverse events, and superior protection to mRNA vaccine technologies.
Hans S. Keirstead, Chairman & Chief Executive Officer, AIVITA Biomedical, Inc.
16:20am Presentation: Okulovision’s Cone Progenitor Cell Therapy for Central Vision Loss
- Cone progenitor cells (cpc) are a pure population of cells that only regenerate cones after subretinal injection, and mediate improved visual function in rodent models
- Cpc are highly proliferative, facilitating manufacture to clinical scale
- Okulovision plans its first clinical trial in patients with cone dystrophies, then advance to patients with macular degeneration.
Marie Csete, Chief Executive Officer, OkuloVision
16:35pm Closing Panel with Q&A
With all session participants